The GeneRide platform uses a cell's natural DNA repair process to produce durable therapeutic protein expression. The technology enables the insertion of DNA segments into the human genome using a viral vector to deliver the therapeutic gene to the nuclei of a patient's cell via a one-time infusion.

LogicBio's research collaboration and exclusive option agreement with Diiachi Sankyo will focus on the development of treatments for two undisclosed indications. Under the agreement, Daiichi Sankyo has the option to negotiate and acquire worldwide licenses for LogicBio's development programs in the two indications. Financial terms of this collaboration were not disclosed.

LogicBio has also entered into a separate strategic collaboration and option agreement with Canbridge Pharmaceuticals for the development of LB-001, an investigational, in vivo gene editing treatment based on GeneRide for the treatment of methylmalonic acidemia (MMA).

LogicBio is eligible to receive an upfront payment of $10 million. LogicBio is also eligible for options payments, clinical, regulatory, and commercial milestone payments of up to $581 million and up to double-digit royalties on net sales.